Intellia Therapeutics Shares Plunge Following Clinical Trial Fatality

A severe clinical setback has triggered a massive sell-off in Intellia Therapeutics stock, with shares plummeting more than 22% during Friday’s trading session. The decline follows the tragic death of a patient participating in a gene-editing study, dramatically intensifying a crisis that began when U.S. regulators imposed a clinical hold in late October.

The biotech company’s stock collapse commenced with a devastating Thursday evening announcement revealing that a patient treated with its lead drug candidate, nexiguran ziclumeran (nex-z), had died. The patient initially experienced severe liver damage on October 27, with the fatal outcome occurring on November 5.

This tragedy strikes during an already precarious period for the company. Read more...